Trial reportBreast cancer research : BCR2005
Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring.
Trial report in Breast cancer research : BCR, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Trial
- Article
- Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer.Journal of personalized medicine · 2021Review
- High depletion of breast cancer cells from the peripheral blood with the method of non-specific separation.Ecancermedicalscience · 2020Article
- Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment.Cancers · 2019Article
- Liquid biopsy: expanding the frontier of circulating biomarker discovery and validation in breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- Circulating tumor cells in thyroid carcinoma - the prognostic role of this biomarker. Review of the literature.Clujul medical (1957) · 2017Review
- Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine.BioMed research international · 2017Review
- Static micro-array isolation, dynamic time series classification, capture and enumeration of spiked breast cancer cells in blood: the nanotube-CTC chip.Nanotechnology · 2016Article
- Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging.Oncology letters · 2016Article
- Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.Breast cancer research : BCR · 2016Article
- The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.Breast cancer research : BCR · 2013Article
- Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells.Journal of translational medicine · 2012Article
- The state of molecular biomarkers for the early detection of lung cancer.Cancer prevention research (Philadelphia, Pa.) · 2012Review
- Strategies for the discovery and development of therapies for metastatic breast cancer.Nature reviews. Drug discovery · 2012Review
- Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma.Journal of cancer research and clinical oncology · 2011Article
- Circulating tumor cells: approaches to isolation and characterization.The Journal of cell biology · 2011Review
- Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progression.Pathology research international · 2011Article
- Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.BMC cancer · 2010Article
- Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment.Journal of cancer research and clinical oncology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn adjuvant treatment for breast cancer there is no tool available with which to measure the efficacy of the therapy. In contrast, in neoadjuvant therapy reduction in tumour size is used as an indicator of the sensitivity of tumour cells to the agents applied. If circulating epithelial (tumour) cells can be shown to react to therapy in the same way as the primary tumour, then this response may be exploited to monitor the effect of therapy in the adjuvant setting.
methodWe used MAINTRAC analysis to monitor the reduction in circulating epithelial cells during the first three to four cycles of neoadjuvant therapy in 30 breast cancer patients.
resultsMAINTRAC analysis revealed a patient-specific response. Comparison of this response with the decline in size of the primary tumour showed that the reduction in number of circulating epithelial cells accurately predicted final tumour reduction at surgery if the entire neoadjuvant regimen consisted of chemotherapy. However, the response of the circulating tumour cells was unable to predict the response to additional antibody therapy.
conclusionThe response of circulating epithelial cells faithfully reflects the response of the whole tumour to adjuvant therapy, indicating that these cells may be considered part of the tumour and can be used for therapy monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.